Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled Xilonix study in refractory metastatic colorectal cancer
NL-OMON45233Phase 3Active, not recruiting
- Sponsor
- XBiotech Inc.
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Xilonix + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Jun 2016; status: active, not recruiting.
02
Drugs
bermekimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON45233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45233.